LYMPHOMAS
Latest News
Latest Videos
CME Content
More News
Viola Poeschel, MD, discusses the results for the phase III FLYER trial in which the standard 6 cycles of R-CHOP were compared to a reduced 4 cycles of R-CHOP in patients with diffuse large B-cell lymphoma
Viola Poeschel, MD, discusses findings from the phase III FLYER trial and how they will impact the treatment landscape for younger patients with favorable-prognosis DLBCL.<br />
According to findings from the phase IIb SADAL study, selinexor demonstrated deep and durable responses in patients with relapsed/refractory diffuse large B-cell lymphoma who are not candidates for autologous stem cell transplantation.
Victor A. Chow, MD, discusses findings of a retrospective study that looked at 55 patients with various B-cell lymphomas who progressed after treatment with CD19-specific CAR T cells.
The use of brentuximab vedotin in combination with chemotherapy has been recommended for approval by the European Medicines Agency’s Committee for Medicinal Products for Human Use as a frontline treatment for adult patients with CD30+ stage IV Hodgkin lymphoma.
Sattva S. Neelapu, MD, discusses the main takeaway from 2-year follow-up data from the ZUMA-1 trial looking at axicabtagene ciloleucel in patients with refractory large B-cell lymphoma.
In findings reported during the 2018 ASH Annual Meeting, brentuximab vedotin with conventional chemotherapy significantly improved progression-free survival compared with standard therapy for nonpediatric patients with stage III/IV Hodgkin lymphoma.
According to findings from the phase III ECHELON-2 trial presented at the 2018 ASH Annual Meeting, the use of brentuximab vedotin (Adcetris) in combination with chemotherapy demonstrated a clinically meaningful improvement in progression-free survival and overall survival in patients with CD30-expressing peripheral T-cell lymphoma. These data were also published online in <em>Lancet Oncology</em>.
A look back at all the FDA news that happened in the month of November 2018, including several new approvals, priority reviews, a fast track designation, and an accelerated approval, across a variety of cancer types.
Two-year findings from the ZUMA-1 trial showed an overall survival rate of more than 50% from treatment with axicabtagene ciloleucel, a CD19-targeted CAR T-cell therapy in patients with refractory large B cell lymphoma; the median survival had not yet been reached. These data, representing a clear plateau in the survival curve, were presented at the 2018 ASH Annual Meeting.
Lenalidomide in addition to rituximab, called the R<sup>2</sup> regimen, led to a significant increase in progression-free survival compared with rituximab alone in patients with relapsed/refractory indolent non-Hodgkin lymphoma in results from the phase III AUGMENT trial.
Overall survival was more than doubled when the CD79b-targeted antibody–drug conjugate polatuzumab vedotin was added to treatment with bendamustine and rituximab for patients with relapsed/refractory diffuse large B-cell lymphoma.
Mosunetuzumab, a CD3 and CD20 bispecific antibody, induced complete remission rates over 30% in patients with relapsed/refractory follicular lymphoma and relapsed/refractory diffuse large B-cell lymphoma or transformed follicular lymphoma, and demonstrated a tolerable safety profile, showing promise for these patients with B-cell indolent and aggressive non-Hodgkin lymphomas.
According to findings from the FLYER trial presented at the 2018 ASH Annual Meeting, treatment with 2 fewer frontline cycles of R-CHOP greatly reduced toxicity in younger patients with low-risk diffuse large B-cell lymphoma. The progression-free survival rates were also similar between the 2 arms.
Victor Chow, MD, senior hematology-oncology fellow, University of Washington, Fred Hutchinson Cancer Research Center, Seattle Cancer Care Alliance, discusses a retrospective study assessing outcomes of patients with large B-cell lymphomas and progressive disease following CD19-Specific CAR T-cell therapy during the 2018 ASH Annual Meeting.
After a median of 19 months of follow-up, durable objective response rates were sustained with tisagenlecleucel in patients with relapsed or refractory diffuse large B-cell lymphoma. These updated findings from the phase II JULIET study were presented at the 2018 ASH Annual Meeting.
Two variants of the chemotherapy regimen R-CHOP resulted in comparable overall survival and progression-free survival in patients with previously untreated stage III or IV indolent B-cell lymphoma, including grades 1 to 3 follicular lymphoma, according to a long-term follow-up analysis from a combined phase II/III randomized trial.
The immunomodulating agent lenalidomide induced a complete response in 74% of patients with high tumor burden follicular lymphoma when used in combination with rituximab and a 4-drug chemotherapy regimen, according to a recent study.
Waldenstrom Macroglobulinemia in a Newly Diagnosed Patient